Hybrigenics SA is a biopharmaceutical company specializing in the development of inecalcitol, a vitamin D receptor agonist, aimed at treating various medical conditions. The company operates primarily in the biotechnology and pharmaceutical sectors, focusing on protein interaction services through its subsidiary, Hybrigenics Services SAS. This subsidiary is recognized as the market leader in Yeast Two Hybrid (Y2H) and other protein interaction services, which are essential for understanding protein functions and interactions in biological research.

Hybrigenics serves a diverse range of clients, including academic institutions, pharmaceutical companies, and biotechnology firms, providing them with advanced tools and services for protein interaction studies. The company's business model revolves around offering specialized research services and developing proprietary pharmaceutical compounds. Revenue is generated through service contracts, research collaborations, and the commercialization of its biopharmaceutical products.

Keywords: biopharmaceutical, inecalcitol, vitamin D receptor, protein interaction, Yeast Two Hybrid, biotechnology, pharmaceutical, research services, market leader, protein functions.